Grünenthal is an independent multinational pharmaceutical company dedicated to research. Since its founding in 1946 until today it has been a family business. Grünenthal and its products are represented in over 100 countries and the number of branches increases continuously. Grünenthal has, globally, around 5,300 employees who are key to the success of the company. Innovative research is an important factor of our company policy to secure the future. Grünenthal has the ambition to belong to the leading companies in research and development in selected therapeutic areas: pain is our central field. In 1998 Grünenthal formally started operations in Mexico and focusing on the therapeutic areas of ‘pain relief’, gynecological infections and treatments, offering to physicians and their patients products and services of the highest quality.
Periférico Sur 5991
Col. Arenal Tepepan, Del. Tlalpan
CP 14610 México DF
MÉXICO
www.grunenthal.com
Latin America continues to be in the spotlight at Grünenthal. The managing director for Mexico explains how the company is strengthening its product portfolio, working with stakeholders to create more…
Grünenthal first started operations in Mexico back in 1998, we then interviewed Mr. Klaus Kuchen in 2005, but we want to know what’s happened since. Please can you give us…
First of all, can you tell us about the history of Andromaco and what have been its major milestones and challenges over the years? This year marks the eightieth anniversary…
Gelpharma started in 1999 and its main strength lies in manufacturing. Please can you give us a more detailed history of the company and its major milestones since opening? We…
First of all, congratulations on the new distribution warehouse in Lerma, State of Mexico . You mentioned that there were two more to come: can you give us a bit…
The company Cryopharma was founded in 1954 with 10 employees. Today, you have fantastic facilities here in the state of Jalisco, and have grown the company to an entire group…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
Sanofi acquired Kendrick in 2009. Obviously the thinking behind it was to diversify your products into pure generics, but what were the expectations for the move? We have a diversified…
Mexico is number one in child obesity and number two in adult obesity in the world. This is one of the reasons that diabetes is rapidly increasing and the Mexican…
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Please can you tell us in your own words how you’ve seen the Mexican pharmaceutical market change over the past five years? Mexico is one of the top ten markets…
You arrived to the position of Boehringer Ingelheim Mexico’s General Director in 2010, what are some of the most exciting milestones and achievements you have presided over during this time?…
Please can you give us a brief rundown of Pierre Fabre’s activities in Mexico since they opened an affiliate here, specifically the company’s milestones and achievements along the way? Pierre…
See our Cookie Privacy Policy Here
